CN102199608B - Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor - Google Patents
Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor Download PDFInfo
- Publication number
- CN102199608B CN102199608B CN201110069545.4A CN201110069545A CN102199608B CN 102199608 B CN102199608 B CN 102199608B CN 201110069545 A CN201110069545 A CN 201110069545A CN 102199608 B CN102199608 B CN 102199608B
- Authority
- CN
- China
- Prior art keywords
- pta
- recombinant
- cell
- bombyx mori
- pinellia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 93
- 241001522129 Pinellia Species 0.000 title claims abstract description 26
- 239000000910 agglutinin Substances 0.000 title claims abstract description 24
- 101710186708 Agglutinin Proteins 0.000 title claims abstract description 13
- 101710146024 Horcolin Proteins 0.000 title claims abstract description 13
- 101710189395 Lectin Proteins 0.000 title claims abstract description 13
- 101710179758 Mannose-specific lectin Proteins 0.000 title claims abstract description 13
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 title claims abstract description 13
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 title claims abstract description 13
- 230000014509 gene expression Effects 0.000 title claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 241000701447 unidentified baculovirus Species 0.000 claims abstract description 30
- 241000700605 Viruses Species 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 201000007270 liver cancer Diseases 0.000 claims abstract description 14
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 58
- 241001522232 Pinellia ternata Species 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 16
- 108090001090 Lectins Proteins 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 238000001890 transfection Methods 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 108020005202 Viral DNA Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 210000002751 lymph Anatomy 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 108091093088 Amplicon Proteins 0.000 claims description 3
- 241000255791 Bombyx Species 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 101150108780 pta gene Proteins 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 241000382353 Pupa Species 0.000 abstract 1
- 230000000857 drug effect Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 18
- 239000007788 liquid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 102100039824 Pre T-cell antigen receptor alpha Human genes 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000012797 qualification Methods 0.000 description 7
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 239000013599 cloning vector Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000013320 baculovirus expression vector system Methods 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 229940047431 recombinate Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920001872 Spider silk Polymers 0.000 description 1
- -1 Spiro Enol Ether Chemical class 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention belongs to the technical field of genetic engineering for producing protein drugs in the biotechnology pharmaceutical engineering. Pinellia ternate agglutinin (PTA) is efficiently expressed by using bombyx mori baculovirus. The recombined virus is inoculated into the larvae and the pupa of the domestic silkworm for expressing PTA through constructing recombined baculovirus containing PTA gene, separated, purified, froze and dried to preserve. A substantial effect for inhibiting liver cancer can be demonstrated by tests on animals, and the method becomes a novel method for preparing cancer treatment medicine. The invention has advantages of easy raw material obtaining, low production cost, easy large-scale mass production and good drug effect, which has quite wide application prospects in market development.
Description
The present invention relates to and utilize the silkworm reactor to express preparation and the anticarcinogen activity research thereof of three leaf pinellia agglutinins (Pinellia ternata agglutinin, PTA).
Three leaf pinellia agglutinins (Pinellia ternata agglutinin, PTA) be a kind of three leaf pinellins with blood coagulation activity of separating from the three leaf tuber of pinellia, there is the character with seminose and the single-minded combination of polymkeric substance thereof, Recent study finds that three leaf pinellia agglutinins energy and eugonic liver cancer cell are in conjunction with making its aggegation and inducing its apoptosis, can suppress the mankind and animal retrovirus (comprising HIV), and also played the important pharmaceutical uses such as remarkable effect in reproduction and contraception, become the focus of Recent study.Baculovirus expression vector system is high eukaryotic expression system; since nineteen eighty-three creates; existing over one hundred kind of foreign gene is at this system expression; due to the protection of a large amount of albumen that silkworm lymph principal body is arranged and the effect of some unknown mechanisms; make the albumen that utilizes this system expression there is high activity; utilize the high efficient expression pharmaceutical protein of silkworm reactor, can there is equal medical active with natural pharmaceutical protein, there is great research application prospect.
Therefore this research adopt baculovirus expression vector system respectively in silkworm larva and silkworm chrysalis high efficient expression there are three leaf pinellia agglutinins of high pharmaceutical use, show that through animal experiment people's liver cancer is had to significant restraining effect, become a kind of novel method for preparing the disease medicaments such as treatment cancer.
The invention provides the escherichia coli plasmid pEasy T1-pta that contains three leaf Lectin Gene from Pinellia Ternatas, the total RNA extracted from the three leaf tuber of pinellia of take is template, by the RT-PCR technology, the clone obtains three leaf half hap genes, introduce restriction enzyme site Nco I and Xho I, TA is connected in T carrier pEasy T1, build cloning vector plasmids pEasy T1-pta, errorless through sequence verification.
The present invention also provides the silkworm baculovirus metastasis transplanting physique grain that contains three leaf Lectin Gene from Pinellia Ternatas pFastBac
tMhTA-pta.The cloning vector plasmids pEasy T1-pta that will contain three leaf Lectin Gene from Pinellia Ternata fragments after Nco I and Xho I double digestion with transfer vector pFastBac through Nco I and Xho I double digestion
tMhTA connects, the recombinant transfer vector plasmid pFastBac of acquisition
tMhTA-pta.
The present invention also provides and has contained three leaf Lectin Gene from Pinellia Ternata recombinant Bombyx mori baculovirus Bm-Bac-pta.By recombinant transfer vector pFastBac
tMhTA-pta is transformed into containing in the intestinal bacteria DH10Bac of viral DNA, by the fixed point swivel base, obtaining restructuring Bacmid DNA, by liposome-mediated transfection silkworm cultured cell, after obvious virus infection symptom occurring, gets supernatant results recombinant virus Bm-Bac-pta.
The present invention also provides the expression product of three leaf Lectin Gene from Pinellia Ternatas in silkworm larva and silkworm chrysalis.By recombinant Bombyx mori baculovirus Bm-Bac-pta transfection silkworm egg parent cell amplicon virus and improve its titre, then by the amplification after recombinant Bombyx mori baculovirus Bm-Bac-pta be seeded to five age silkworm larva and the silkworm chrysalis body in, reclaim silkworm lymph blood and pupal cell, separation and purification freeze-drying are preserved (with reference to " Silkworm, Bombyx mori larvae expressed the spider silk protein through a novel Bac-to-Bac/BmNPV baculovirus " Journal of Applied Entomology 2006; 130:297-301).
The present invention has also carried out bioactive evaluation to the expression product of three leaf Lectin Gene from Pinellia Ternatas.The biologic activity of expression product is similar to natural three leaf pinellia agglutinins, and rabbit blood is had to agglutination.
The present invention has carried out the Anticancer experiment to utilizing the silkworm reactor to express three leaf Lectin Gene from Pinellia Ternatas.Utilize three leaf pinellia agglutinins that baculovirus expression vector system expresses in silkworm larva and silkworm chrysalis to there is significant restraining effect to the people's of vitro culture liver cancer cell Bel-7402.
The invention provides following:
1. a leaf pinellia agglutinin (Pinellia ternata agglutinin, PTA) gene, PTA gene order (AY451854.1) comparison that itself and NCBI report shows the 24th, 25, 47, 56, 59, 67, 69, 72, 85, 90, 104, 108, 115, 127, 129, 133, 148, 149, 151, 177, 298, 241, 255, 264, 267, 273, 280, 281, 287, 288, 308, 311, 316, 325, 326, 327, 331, 348, 381, 412, 415, 416, 427, 433, 437, 441, 463, 470, 474, 475, 483, 485, 490, 504, 508, 511, 547, 550, 552, 562, 586, 598, 606, 634, 638, 648, 703, 706, 714, 741, 742, 744, 750, 766, 771, 772, 773, corresponding base such as 774 78 of grades has significant difference.
2.1 gene, its nucleotide sequence is the sequence shown in SEQ ID NO:1:
CTACGCAGCAATGGAGCGCTTCGAGTTGGTCTCAAAGATGGCAGGGCCGTAGATGACGCCGAAGCCGTTCTCTTGGAGGATGAAGACGTAGTCACCCTGCTTGGAGCTGGACTGGCTGCTCCAGATTGTCTTGAAGTTGTCGTCCTTGATGATGAGCTCGCCCTTGTGGCTCAGCCTGAGGAAGCAGTGGTCGCCGTTGCCGTGGGTGTTGGATTGCCAGCCGAATTTGCCGCCGTACAGGACCAGGTTGCAGTCGCCCTGCATCACGAGCTTGTGGTTCCTCGCCGTGAGCCTGCCGTCTTCGTGGAGGACTTGGCCGGAGAAGAGCATGTTGTCGGTGACAGGGATGTTGCCGAGCTGCCGCAGGCTGTTGAGGCCGGGGACCCAAGGGTTAATCTTGAAGACGGATGGGCCGTAGATGACCAGCTTCCCCTCCGGATGGACGACCAAGGCGTAGTCGCCCCTCTCGGACTGGGAGCCGCTCCTAAAGACGATGGATCCG TCGCCATTCTTGATGATGAGCTCGCCGCGGTTGGTGAGGGTGAGCTTGCAGTCCCGTCCTTTGTTGGCCGTGTTGGACTGCCAGTTGCCGTTGTAAAGGACGGCGTTGCAGTCTTCCTGCATTACCAAGTCGAAGTCGCCGTTCCTGAGATGGCCGTTCGTGTCCAGGATCTCGCCGGACAGCAGGTGGTTGGTGCCCACTGCCGCGGCTGCCCGGGGAATGACGAGGCCGAGGATGGCCGGGAGGAATAAGAGGAGGAGCTTGGAGGCCAT(SEQ ID NO:1)。
3. a protein, it is by 1 or 2 described gene orders codings.
4. a recombinant vectors, it comprises 1 or 2 described gene nucleic acid sequences.
5.4 described recombinant vectors, it is based on pEasy T1, pFastBac
tMhTA, pFastBac
tMhTB, pFastBac
tMhTC or pFastBac
tM1 structure.
6. a silkworm host cell, it can express 1 or 2 described gene nucleic acid sequences under applicable expression condition.
7.6 described silkworm host cell, it is the ovocyte BmN that takes from silkworm (Jingsong×Haoyue strain).
8. a recombinant Bombyx mori baculovirus, it is to be transformed into containing in the competent cell of viral DNA, by the fixed point swivel base, obtaining restructuring Bacmid DNA by the recombinant vectors by 4 or 5, by liposome-mediated transfection silkworm egg parent cell, after obvious virus infection symptom occurring, get that supernatant reclaims and obtain.
9.8 described recombinant Bombyx mori baculovirus, the described competent cell containing viral DNA is intestinal bacteria DH10 Bac.
10.8 described recombinant Bombyx mori baculovirus, described silkworm egg parent cell is the BmN cell.
11.8 described recombinant Bombyx mori baculovirus, it is in the center preservation of China Committee for Culture Collection of Microorganisms's common micro-organisms, and preserving number is CGMCC No:3677.
12.1 or 2 described gene orders, 3 described protein, 4 or 5 described recombinant vectorss, 6 or 7 described silkworm host cells, the described recombinant Bombyx mori baculovirus of 8-11 is for the preparation of the application of antitumor drug.
13.12 application, wherein said tumour is liver cancer.
14.13 application, wherein said liver cancer cell is Bel-7402.
15. the shaft-like virus expression systems of silkworm reactor, wherein by the recombinant Bombyx mori baculovirus transfection silkworm egg parent cell amplicon virus of 8-11 and improve its titre, then the recombinant Bombyx mori baculovirus after amplification is seeded to the expression of carrying out three leaf pinellia agglutinins in silkworm larva and silkworm chrysalis body, reclaim silkworm lymph blood and pupal cell, separation and purification freeze-drying are preserved.
16., according to the shaft-like virus expression systems of 15 described silkworm reactor, wherein said silkworm egg parent cell is Bombyx noriN cell.
17., according to the shaft-like virus expression systems of 15 described silkworm reactor, the wherein said recombinant Bombyx mori baculovirus that contains three leaf Lectin Gene from Pinellia Ternatas is Bm-Bac-pta, its structure is by by recombinant transfer vector pFastBac
tMhTA-pta is transformed into containing in the intestinal bacteria DH10Bac of viral DNA, by the fixed point swivel base, obtaining restructuring Bacmid DNA, by liposome-mediated transfection silkworm egg parent cell, after obvious virus infection symptom occurring, get supernatant and reclaim to obtain that recombinant Bombyx mori baculovirus carries out.
18. one kind is utilized the shaft-like virus expression systems of silkworm reactor of any one in 15-17 to express three leaf Lectin Gene from Pinellia Ternatas and the method for the preparation of antineoplastic protein medicaments by described expression product.
19.18 method, wherein said tumour is liver cancer.
To sum up, three leaf pinellia agglutinins of the expression in silkworm larva and silkworm chrysalis have high pharmaceutical use; Silkworm is can the low-cost extensive economic insects of raising; multiple natural protein protective material is arranged in the silkworm body; expression product is had to provide protection; make gene expression product very stable; be easy to extensive High-efficient Production; and the pharmaceutical protein structure function at this system expression is close with natural pharmaceutical protein, and have very high medical active, research and market development application prospect are very wide.
It should be noted that the silkworm host cell that comprised in the present invention, refer to the somatocyte of silkworm.
The accompanying drawing explanation:
Fig. 1 pFastBac
tMthe HTA-pta enzyme is cut and is identified and PCR evaluation figure; It is 0.8% agarose electrophoresis figure.
Fig. 2 Bacmid-pta take M13 as primer, PAHL be primer PCR evaluation figure.
Fig. 3 recombinate Bacmid/BmNPV/pta take M13 as primer, PAHL be primer PCR evaluation figure.
Fig. 4 Bacmid-pta DNA transfection bombyx mori cell comparison diagram of recombinating; Wherein A figure is negative control figure (10 * 10); B figure is the cell picture (10 * 10) of transfection after five days, and C figure is negative control figure (20 * 10); D figure is the cell picture (20 * 10) of transfection after five days.
Figure is identified in the 12%Tris-glycine SDS-PAGE gel electrophoresis of Fig. 5 PTA fusion rotein.
The microphotograph figure of the purified rear aggegation rabbit erythrocyte of Fig. 6 PTA.A is normal rabbit erythrocyte (negative control); B is the rabbit erythrocyte microgram added after PTA solution.
The inhibition figure of the PTA that Fig. 7 utilizes mtt assay to detect to express in silkworm to liver cancer cell.
Fig. 8 pta gene order provided by the invention and the pta gene order BLAST comparison result figure reported.
Fig. 9 is containing pta gene recombination cloning vector plasmids pEasy T1-pta.
Figure 10 is containing the recombinant Bombyx mori baculovirus metastasis transplanting physique grain pFastBac of pta gene
tMhTA-pta.
The present invention constructed containing the recombinant Bombyx mori baculovirus PTA silkworm-P4 of three leaf Lectin Gene from Pinellia Ternatas on April 2nd, 2010 at China Committee for Culture Collection of Microorganisms's common micro-organisms center (No. 3, No. 1, Chaoyang District Beijing North Star West Road institute, Institute of Microorganism, Academia Sinica, 100101) carried out preservation, deposit number is CGMCC No:3677.
specific embodiments
Below embodiments of the invention are elaborated: as prerequisite under implemented take by technical solution of the present invention for the present embodiment, provided detailed embodiment and concrete operating process.
recombinant transfer vector plasmid pFastBac
tM
the structure of HTA-pta, screening and evaluation
1. utilize RT-PCR to clone from three leaf tuber of pinellia stem tubers and obtain three leaf Lectin Gene from Pinellia Ternatas (SEQ ID NO:1), build recombinant cloning vector plasmid pEasy T1-pta, and be converted in E.coli DH5 α and increase, extract containing the cloning vector plasmids pEasy T1-pta (TransGen) of goal gene (SEQ ID NO:1) and the metastasis transplanting physique grain pFastBac of baculovirus expression system
tMhTA (Invitrogen).
2. by above-mentioned plasmid double digestion, system is as follows:
3. by the pta fragment of purifying (SEQ ID NO:1) and pFastBac
tMthe HTA fragment connects, and reaction conditions is as follows:
2×ligase Buffer 5μL
Pta fragment 3 μ L
T4 DNA Ligase 1μL
pFastBac HTA 1μL
4 ℃ of connections are spent the night.
4. get above-mentioned connection product 5 μ L, be added in 200 μ L E.coli DH5 α competent cell suspensions, mix gently, place 30min on ice; 42 ℃ of water-bath heat shock 90sec, take out and put cooled on ice 3-5min rapidly; Add the LB liquid nutrient medium (containing microbiotic) of 37 ℃ of preheatings of 1mL, mix rear 37 ℃ of water-bath 1h, make the bacterium state that restore normal growth; The centrifugal 10min of 4000rpm, abandon the 1mL supernatant, precipitates after resuspended to get approximately 200 μ L and evenly coat on the LB flat board containing Amp and Gen, and 37 ℃ face up and place 30min, are inverted after bacterium liquid is absorbed by substratum fully and cultivate 10-16h.
5. with the single bacterium colony of the aseptic toothpick white that 3 growth conditions of picking are good from transforming flat board, be inoculated in respectively in the 5mL LB liquid nutrient medium containing Amp and Gen 50 μ g/mL, 37 ℃, 220rpm shaking culture 8-10h;
6. get respectively the 1.5mL nutrient solution and pour in 1.5mL Eppendorf pipe, 4 ℃, the centrifugal 30sec of 12000rpm;
7. abandon most supernatant, bacterial sediment is resuspended in 100 μ L solution I (25mMTris-HCl, 10mM EDTA, 50mM Glucose) of precooling, and the vortex vibration mixes; Ice bath 10min;
8. add freshly prepared solution II (200mM NaOH, 1% (w/v) SDS) 200 μ L, leniently put upside down the Eppendorf pipe 5 times, ice bath 5min, make solution become clarification;
9. the solution III (3M KOA, the 5M CH that add 150 μ L precoolings
3cOOH), and be inverted centrifuge tube, vibration 30sec, ice bath 5min, 4 ℃, the centrifugal 10min of 12000rpm;
10. careful sucking-off supernatant liquor proceeds in clean Eppendorf pipe, adds isopyknic phenol: chloroform: primary isoamyl alcohol (25: 24: 1), and put upside down and mix, 4 ℃, the centrifugal 5min of 12000rpm;
11. supernatant liquor is moved in clean Eppendorf pipe, add the dehydrated alcohol of 2 times of volumes and the 3mol/L NaAc (pH5.2) of 1/10 volume, put upside down and mix rear room temperature placement 5min;
12.4 ℃, the centrifugal 10min of 12000rpm;
13. abandon supernatant, add 70% ethanol of 1mL precooling to wash precipitation once, vacuum-drying 5min or drying at room temperature; The plasmid precipitation obtained is dissolved in to the aseptic ddH of 50 μ L
2o, add RNaseA (20 μ g/mL), and 37 ℃ of water-bath 30-60min, take a morsel respectively by the purity of 0.8% agarose gel electrophoresis Detection and Extraction plasmid, and other is in-20 ℃ of preservations.Recombinant plasmid is according to different carrier called afters: pFastBac
tMhTA-pta.
14. using the plasmid that extracts as template, carry out the PCR evaluation.
PAHL primer 1:
5’-GGACCATGGATGGCCTCCAAGCTCCTCC-3’
PAHL primer 2:
5’-GGACTCGAGCTACGCAGCAATGGAGCGC-3’
The PCR reaction system is:
The response procedures of PCR is:
94℃5min;94℃45sec,65℃45sec,72℃45sec,30cycles;72℃10min
15.PCR be accredited as positive plasmid, further identify by the method for double digestion.
In aseptic Eppendorf pipe, add successively:
After 37 ℃ of incubation 4h, detect enzyme with 0.8% agarose gel electrophoresis and cut result.
16.pFastBac
tMthe HTA-pta enzyme cut and the PCR qualification result as shown in Figure 1, agarose gel electrophoresis figure result is from left to right Marker successively, pFastBac
tMthe HTA-pta enzyme is cut result, pFastBac
tMhTA-pta PCR qualification result band.Enzyme is cut with PCR and is identified that corresponding band conforms to theoretical value.
Embodiment 2
the restructuring Bacmid-pta structure and obtain
1. get the recombinant plasmid pFastBac of the above-mentioned structure of 5 μ L
tMhTA-pta, be added in 200 μ LDH10Bac competent cell suspensions, mixes gently, places 30min on ice;
2.42 ℃ water-bath heat shock 45sec, take out and put cooled on ice 3-5min rapidly;
3. add the LB liquid nutrient medium (containing microbiotic) of 37 ℃ of preheatings of 1mL, mix rear 37 ℃ of water-bath 4h, make the bacterium state that restore normal growth;
4. by the centrifugal 10min of bacterium liquid 4000rpm transformed, abandon the 1mL supernatant, precipitate after resuspended and get approximately 200 μ L nutrient solutions.
5. get 100 times of 20 μ L bacterium liquid dilutions, then add 5 μ L X-gal and 5 μ L IPTG to mix, get bacterium liquid 100-200 μ L and coat LB flat board (containing Tet, Gen, Kan) above, 37 ℃ of lucifuges that face up are placed 30min, be inverted lucifuge and cultivate 48h after bacterium liquid is absorbed by substratum fully.As the restructuring donor plasmid pFastBac that contains foreign gene
tMhTA-pta transforms DH10Bac competent cell (Invitrogen) (this cell contains baculovirus shuttle vectors Bacmid, Kanr and replicon and LacZ peptide section encoding gene), foreign gene in donor plasmid is under the transposase effect of helper plasmid coding, be inserted in the Baculovirus Gene group by swivel base, destroyed the expression of LacZ.By the culture plate screening that contains kantlex, gentamicin, tsiklomitsin and X-gal, the Bacmid of restructuring (being recombinant virus genomes) transformant bacterium colony is white in color, but not restructuring Bacmid transforms bacterium colony, is blue.
6. the single bacterium colony of DH10Bac transformant white that 4 growth conditions of picking are good from blue hickie screening is dull and stereotyped with aseptic toothpick, be inoculated in respectively in the 5mL LB liquid nutrient medium containing 50 μ g/mLl Kan, 7 μ g/mL Gen and 10 μ g/mL Tet, 37 ℃, 220rpm shaking culture 8-10h.To be put into 4 ℃ of refrigerators after stable standby Deng bacterial classification; 7. get respectively the 1.5mL nutrient solution and pour in 1.5mL Eppendorf pipe, 4 ℃, the centrifugal 1min of 14000rpm;
8. abandon most supernatant, bacterial sediment is resuspended in 300 μ L solution I (25MmTris-HCl, 10mM EDTA, 50mM Glucose) of precooling, with the piping and druming gently repeatedly of imbibition rifle;
9. add freshly prepared solution II (200mM NaOH, 1% (w/v) SDS) 300 μ L, piping and druming, mix it gently;
10. slowly add the liquor kalii acetici that 300 μ L pH values are 5.5, the limit edged mixes gently, ice bath 5-10min;
11. under 4 ℃, the centrifugal 10min of 14000rpm;
12. supernatant liquor is transferred in new Eppendorf pipe gently, add 800 μ L Virahols, and repeatedly be inverted gently, liquid is fully mixed, then ice bath 5-10min.Room temperature, the centrifugal 15min of 14000rpm;
13. carefully remove supernatant liquor, add the ethanol of 500 μ L 70%, the Eppendorf pipe is inverted several times repeatedly gently, liquid is fully mixed;
14. the centrifugal 5min of 14000rpm at room temperature.Repeat the 7-8 step;
15. supernatant liquor is fully removed and, carefully in case the dissolving once again of restructuring Bacmid DNA is at room temperature placed 5-10min by the DNA be settled out and dried, must guard against overdrying;
16. will recombinate, Bacmid DNA is dissolved in 1 * TEBuffer that 40 μ L pH values are 8.0 again, avoids acutely shaking in case DNA break.Allow to jiggle the DNA that is positioned at Eppendorf pipe bottom is fully dissolved;
17. restructuring Bacmid DNA is stored under 4 ℃ of environment, for analysis or for being transfected into bombyx mori cell, by described restructuring Bacmid DNA called after Bacmid-pta.
18. using the Bacmid-pta that extracts as template, by M13 upstream primer and the M13 downstream primer purpose fragment that increases, carry out the PCR evaluation.
The M13 upstream primer: 5 '-GTTTTCCCAGTCACGAC-3 '
The M13 downstream primer: 5 '-CAGGAAACAGCTATGAC-3 '
The PCR reaction system is:
The response procedures of PCR is:
93℃3min;94℃45sec,58℃45sec,72℃5min,30cycles;72℃7min
19. the PCR qualification result of restructuring Bacmid-pta as shown in Figure 2, respectively to the M13 universal primer, the Auele Specific Primer pcr amplification is identified.Shown in figure, be from left to right Marker successively, take M13 as the primer qualification result, the qualification result that the PAHL of take is Auele Specific Primer, its qualification result all conforms to theoretical value.
Embodiment 3
the acquisition of recombinant Bombyx mori baculovirus (recombinant Bacmid/BmNPV/pta)
1. silkworm egg parent cell BmN (purchased from Shanghai cell research institute of the Chinese Academy of Sciences) cultivates at the Grace ' s substratum (Invitrogen) that contains foetal calf serum in the CO of 27 ℃
2cultivate in cell culture incubator, cover incubation time 24h-36h to 35mm Tissue Culture Dish (Invitrogen) more than 80%;
2. abandon substratum, add 1mL not contain the Grace ' s substratum of foetal calf serum, 27 ℃ of standing 30min are again adherent to cell;
3. get 10 μ L Cellfectin liposomes (Invitrogen) and mix with the Grace ' s substratum that 250 μ L do not contain foetal calf serum, standing 5min under room temperature;
4. be taken at the Grace ' s substratum that the Bacmid-pta DNA (3 μ g) that builds in above-described embodiment and 250 μ L do not contain foetal calf serum, flick to put upside down and mix, standing 5min;
5. the Cellfectin liposome (Invitrogen) after dilution is joined in the restructuring Bacmid DNA of above-mentioned dilution, put upside down and mix gently, standing 20min;
6. take out 35mm Tissue Culture Dish (Invitrogen), discard insect cell substratum (Invitrogen), drip immediately the mixed solution in step 5, gently shake culture dish, it is uniformly distributed, cultivate 4h for 27 ℃;
7. take out above-mentioned culture dish, add the Grace ' s substratum 2mL that contains foetal calf serum, 27 ℃ are continued to cultivate, and after 72h, cell starts to suspend, and after 120h, this phenomenon is more obvious.Illustrate that bombyx mori cell falls ill, the success of Bacmid-pta transfection silkworm egg parent cell, produce the P1 virus strain;
8. get the cell 5ml of above-mentioned morbidity, it is mixed gently, and transfer in aseptic Eppendorf pipe.The centrifugal 5min of 500rpm, carefully get supernatant liquor (being the P1 virus strain).
9. the titre of P1 virus strain is preset as to 5 * 10
6pfu/mL is that 0.1pfu/cell infects 4 * 10 by MOI
6healthy Bombyx noriN cell, calculate the volume of required P1 virus strain:
Get 80 μ LP1 and infect healthy bombyx mori cell, results P2 virus strain after 72h.The P4 virus strain obtained has thus sent China Committee for Culture Collection of Microorganisms's common micro-organisms center to carry out preservation, and preserving number is CGMCC No:3677.
10. in the silkworm egg parent cell BmN that the Bacmid DNA of restructuring or recombinant virus is seeded in to adherent culture, after the morbidity of cell infection virus, cell will suspend, and as shown in Figure 4, it is large that the cell rounding of virus infection becomes, and suspend.Restructuring Bacmid/BmNPV/pta be take M13 as primer, PAHL identify as primer PCR, as shown in Figure 3, is from left to right Marker successively, the evaluation band that the M13 of take is primer, and the evaluation band that the PAHL of take is primer, stripe size all conforms to theoretical value.
Embodiment 4
obtain target protein
I、
1. dip the cell conditioned medium (about 5 * 10 behind the restructuring Bacmid/BmNPV/pta virus 5 sky that infects above-mentioned acquisition with inoculating needle
4pFU recombinant virus particle), subcutaneous from (Jingsong×Haoyue strain) silkworm chrysalis (purchased from Zhongqi Biological Pharmaceutical Co., Ltd., Zhejiang) belly the 5th and the 6th internode puncture access with inoculating needle.Cultivate in 27 ℃ of thermostat containers, treat virus amount reproduction in the silkworm chrysalis body.After about 168h, silkworm chrysalis internode obvious tumefaction, the pupal cell deliquescing, illustrate that silkworm chrysalis falls ill, collects the silkworm chrysalis of recombinant virus infection, lyophilize;
2. by cryodesiccated silkworm chrysalis grind into powder, the PBS damping fluid suspends, ultrasonication, and 4 ℃, the centrifugal 10min of 10000r/min, get supernatant-20 ℃ and save backup and get a little SDS-PAGE detected through gel electrophoresis;
3. Sefinose-6B (purchased from Shanghai traditional Chinese medicines company) the dress post (1.6 * 50cm) of learning from else's experience and processing, use the physiological saline balance.By the affinity chromatography sample physiological saline equilibrium dialysis obtained in step 2, concentrated rear upper prop, with identical physiological saline wash-out, flow velocity is 1mL/min, carries out the half-peak collection, and the sample of collection is all got to a little SDS-PAGE detected through gel electrophoresis;
4. in adding 4mL step 3 in the purification column of the purification column matrix of the nickel NTA sepharose matrix that contains 1mL 50%, gained, containing the protein solution at the corresponding peak of target protein, mixes in 4 ℃ in conjunction with 2h;
5. nickel NTA sepharose affinity column is fixing on the certain altitude upholder, and upper cover is opened bottom and is prepared to be collected with the EP pipe;
6. the pillar bottom is opened, the EP pipe is collected effluent liquid;
7. add the resuspended matrix of 5mL Binding Buffer (20mM Tris-HCl, 500mM NaCl), room temperature is placed 2min, discards effluent liquid;
8. add the resuspended matrix of 5mL Wash Buffer (20mM Tris-HCl, 500mM NaCl, 50mM Imidazde), room temperature is placed 2min, discards elutriant;
9. add the resuspended matrix of 2mL Elution Buffer (20mM Tris-HCl, 500mM NaCl, 500mM Imidazde), room temperature is placed 2min, collects elutriant, concentrated and SDS-PAGE gel electrophoresis check.
II、
Dip the cell conditioned medium (about 5 * 10 infected behind the restructuring Bacmid/BmNPV/pta virus 5 sky obtained in embodiment 3 with inoculating needle
4pFU recombinant virus particle), subcutaneous from (Jingsong×Haoyue strain) silkworm larva in five ages (purchased from Zhongqi Biological Pharmaceutical Co., Ltd., Zhejiang) belly the 5th and the 6th internode puncture access with inoculating needle.Cultivate in 27 ℃ of thermostat containers, treat virus amount reproduction in the silkworm larva body.After about 168h, silkworm larva internode obvious tumefaction, illustrate that silkworm larva falls ill, collects lymph blood, is dissolved in dilution buffer liquid (10mM NaH
2pO
4, 300mMNaCl, 8M urea; PH 8.0), the centrifugal 30min of 12,000 * g, supernatant liquor be stored in-80 ℃ standby.Purge process is with I joint 3 to 9 steps.
As shown in Figure 5, size is about 29KDa to above-mentioned assay, with theoretical value, conforms to, obtain should be the restructuring three leaf pinellia agglutinin proteins.
Embodiment 5
the blood coagulation activity of the three leaf pinellia agglutinin proteins that the present invention obtains is identified.
It is 40 μ gml that the restructuring of purifying in embodiment 4 three leaf pinellia agglutinin proteins are diluted to concentration
-1, upper with 2 times of gradient dilutions of 0.85% physiological saline work at 96 orifice plates (Thermo).Add 10 μ l samples on slide glass, equal-volume mixes 2% rabbit erythrocyte (purchased from Hangzhou Pedagogic University's Experimental Animal Center), and room temperature is placed the 5-10min left and right, the lower blood clotting effect that detects of high power lens (40 *).Make blank with physiological saline.As shown in Figure 6, the rabbit erythrocyte state of A figure negative control group is normal for qualification result; B figure adds the rabbit erythrocyte after restructuring three leaf pinellia agglutinin protein solution agglutination to occur.
Embodiment 6
utilize mtt assay (with reference to " utilize mtt assay with Spiro Enol Ether Analogues to insect cell Virulence Selection and mensuration " Agricultural University Of South China's journal 2000; 21:29-32) antineoplastic activity of the three leaf pinellia agglutinins of recombinating detected.
The liver cancer cell Bel-7402 (purchased from Shanghai cell research institute of the Chinese Academy of Sciences) cultivated is inoculated in sub 96 well culture plates (Thermo), and concentration is 2 * 10
4/ ml.180 μ l are inoculated in every hole, add the restructuring three leaf pinellia agglutinins (sample dissolves with PBS) of above-mentioned preparation after continuation cultivation 24h.The application of sample final concentration is divided into 0.025mg/ml, 0.050mg/ml, 0.100mg/ml (volume is 20 μ l).The every hole of control group adds 20 μ l PBS.Continue to cultivate after 24h every hole and add MTT (take tetrazolium bromide 0.5 gram, be dissolved in the phosphoric acid buffer (PBS) of 100ml or without in phenol red substratum) solution 20 μ l, 37 ℃, hatch 4h.After carefully sucking the nutrient solution in 96 orifice plates.Every hole adds 200 μ l DMSO.The 5min that vibrates on constant temperature oscillator measures each hole OD value in microplate reader (Multiskan MK3 microplate reader).Measuring wavelength is that 492nm. calculates the growth inhibition ratio of each extract to tumour cell.Growth inhibition ratio (%)=(the average OD value of the average OD value/control group of the average OD value-experimental group of control group) * 100%.Utilize mtt assay to the antineoplastic active result detected of the three leaf pinellia agglutinins of recombinating as shown in Figure 7, the restructuring pinellia agglutinin that the present invention obtains is inhibited to liver cancer cell Bel-7402, and inhibition is strengthened along with the increase of the protein concentration added.
Claims (13)
1. a leaf pinellia agglutinin (Pinellia ternata agglutinin, PTA) gene, its nucleotide sequence is the sequence shown in SEQ ID NO:1:
2. a protein, it is encoded by gene order claimed in claim 1.
3. a recombinant vectors, it comprises gene nucleic acid sequence claimed in claim 1.
4. recombinant vectors claimed in claim 3, it is based on pEasy T1, pFastBac
tMhTA, pFastBac
tMhTB, pFastBac
tMhTC or pFastBac
tM1 structure.
5. a recombinant Bombyx mori baculovirus, it is to be transformed in intestinal bacteria DH10Bac competent cell and to obtain restructuring Bacmid DNA by the fixed point swivel base by the recombinant vectors by claim 3 or 4, by liposome-mediated transfection silkworm egg parent cell, after obvious virus infection symptom occurring, get that supernatant reclaims and obtain.
6. recombinant Bombyx mori baculovirus claimed in claim 5, wherein said silkworm egg parent cell is the BmN cell.
7. recombinant Bombyx mori baculovirus claimed in claim 5, it is in the center preservation of China Committee for Culture Collection of Microorganisms's common micro-organisms, and preserving number is CGMCC No:3677.
8. gene order claimed in claim 1, protein claimed in claim 2, the described recombinant vectors of claim 3 or 4, the described recombinant Bombyx mori baculovirus of claim 5-7 is for the preparation of the application of medicines resistant to liver cancer.
9. the application of claim 8, wherein said medicines resistant to liver cancer for liver cancer cell be Bel-7402.
10. a method of expressing three leaf pinellia agglutinins, described method comprises the recombinant Bombyx mori baculovirus transfection silkworm egg parent cell amplicon virus of claim 5-7 and improves its titre, then the recombinant Bombyx mori baculovirus after amplification is seeded to the expression of carrying out three leaf pinellia agglutinins in silkworm larva and silkworm chrysalis body, reclaim silkworm lymph blood and pupal cell, separation and purification freeze-drying are preserved.
11. method according to claim 10, wherein said silkworm egg parent cell is Bombyx noriN cell.
12. method according to claim 10, the wherein said recombinant Bombyx mori baculovirus that contains three leaf Lectin Gene from Pinellia Ternatas is Bm-Bac-pta, and its structure is by by recombinant transfer vector pFastBac
tMhTA-pta is transformed into containing in the intestinal bacteria DH10Bac of viral DNA, by the fixed point swivel base, obtaining restructuring Bacmid DNA, by liposome-mediated transfection silkworm egg parent cell, after obvious virus infection symptom occurring, get supernatant and reclaim to obtain that recombinant Bombyx mori baculovirus carries out.
13. one kind is utilized the method for any one in claim 10-12 to express three leaf Lectin Gene from Pinellia Ternatas and the method for the preparation of the protein medicaments of anti-liver cancer by described expression product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110069545.4A CN102199608B (en) | 2011-03-18 | 2011-03-18 | Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110069545.4A CN102199608B (en) | 2011-03-18 | 2011-03-18 | Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102199608A CN102199608A (en) | 2011-09-28 |
CN102199608B true CN102199608B (en) | 2014-01-08 |
Family
ID=44660595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110069545.4A Expired - Fee Related CN102199608B (en) | 2011-03-18 | 2011-03-18 | Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102199608B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103290041A (en) * | 2012-02-27 | 2013-09-11 | 上海拜生生物科技有限公司 | Construction of factor C from tachypleus tridentatus pronucleus and insect baculovirus recombinant expression vector |
CN112980701A (en) * | 2021-04-17 | 2021-06-18 | 浙江理工大学 | Composite microbial inoculum for promoting germination and growth of dendrobium officinale seeds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101358205A (en) * | 2008-08-29 | 2009-02-04 | 浙江理工大学 | Method for synthesizing protein using in vitro expression system of silkworm baculovirus |
-
2011
- 2011-03-18 CN CN201110069545.4A patent/CN102199608B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101358205A (en) * | 2008-08-29 | 2009-02-04 | 浙江理工大学 | Method for synthesizing protein using in vitro expression system of silkworm baculovirus |
Non-Patent Citations (2)
Title |
---|
徐 陶 等.半夏蛋白及其基因研究进展.《时珍国医国药》.2009,第20卷(第10期),2557-2559. * |
簧必胜.半夏蛋白对人肝癌细胞Bel-7402生长抑制作用的研究.《湖北中医杂志》.2006,第28卷(第12期),11-12. * |
Also Published As
Publication number | Publication date |
---|---|
CN102199608A (en) | 2011-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103585625B (en) | A kind of porcine epizootic diarrhea recombinant baculovirus genetic engineering subunit vaccine and preparation method thereof and application | |
CN103172749A (en) | Preparation of African swine fever protein engineering vaccine | |
CN102120768B (en) | Method for producing curative canine parvovirus virus monoclonal antibody by using bioreactor | |
CN106834352A (en) | The polyhedrosis method of parcel carp herpesviral II type antigens is prepared based on baculovirus expression system | |
CN106540249A (en) | A kind of bird flu (H5N1) or the antigen concentrating and purifying process of Porcine reproductive and respiratory syndrome (PRRS) viral vaccine | |
CN102352347A (en) | Porcin circovirus type 2 (PCV2) recombinant baculovirus construction method and subunit vaccine preparation method thereof | |
CN103184230B (en) | Fusion protein gene TAT-sVP7 and application thereof | |
CN102816246B (en) | Human cytomegalo virus immunogen fusion protein as well as preparation method and usage thereof | |
CN104788568A (en) | Pichia pastoris genetic engineering hybrid antibacterial peptide CC29 and preparing method thereof | |
CN101215576A (en) | Rabbit viral haemorrhagic virus capsid protein gene recombination baculovirus and bacterin | |
CN102199608B (en) | Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor | |
CN103450355B (en) | recombinant bovine alpha interferon and application thereof | |
CN103319608A (en) | Pig IFNalpha1-Fc fusion protein as well as encoding gene and expression method thereof | |
CN106399266A (en) | Recombinant baculovirus for expressing dog serum albumin fused interferon gamma and application of recombinant baculovirus | |
CN104725503B (en) | A kind of Fugu rubripes nervous necrosis virus capsid protein Yolk antibody and its application | |
CN110124025A (en) | A kind of bird flu and 4 type bigeminy genetic engineering subunit vaccine of aviadenovirus and preparation method thereof | |
CN103232545B (en) | A kind of Recombinant Swine Interferon α1-Fc fusion rotein and encoding gene thereof and expression method | |
CN104561098A (en) | Recombinant human lactoferrin (rhLF) silkworm chrysalis powder as well as preparation method and application thereof | |
CN102174110B (en) | Rabies virus glycoprotein-derived peptide and application thereof | |
CN110128545A (en) | A kind of fusion, recombinant expression carrier, antigen and its preparation method and application | |
CN102604993A (en) | Immunologic adjuvant-Helicobacter pylori antigen fused protein oral vaccine and preparation method thereof | |
CN101906423A (en) | Preparation method of recombined human nerve growth factor based on insect baculovirus expression system | |
CN101863976B (en) | Preparation method of EV71 virus antibody | |
CN103468769B (en) | Preparation method containing selenium recombinant human serum albumin | |
CN102703505A (en) | Co-expressed brucella recombinant adenovirus as well as preparation method and use thererof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140108 Termination date: 20140318 |